INM News and Press, InMed Pharmaceuticals Inc. From 03/20/23

2023-03-20 13:07:07 ET Gainers: Loyalty Ventures ( LYLT ) +97% . Ambipar Emergency ( AMBI ) +73% . Lifecore Biomedical ( LFCR ) +60% . InMed Pharmaceuticals ( INM ) +43% . New York Community Bancorp ( NYCB ) +32% . Harbor Cus...

2023-03-20 10:29:09 ET Gainers: Lifecore Biomedical ( LFCR ) +41% . Connect Biopharma ( CNTB ) +27% . InMed Pharmaceuticals ( INM ) +21% . ReShape Lifesciences ( RSLS ) +21% . Bellerophon Therapeutics ( BLPH ) +15% . Losers...

2023-03-13 08:54:26 ET Provention Bio PRVB +263% on ~$2.9B acquisition by Sanofi. Calliditas Therapeutics ( CALT ) +29% announces primary endpoint successfully Met in phase 3 NefIgArd trial evaluating Nefecon® in IgA Nephropathy. Caleminder ( CMND ...

Supports the therapeutic potential of rare cannabinoids in inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne Further demonstrates the anti-inflammatory effects of CBC, THCV, CBG and CBGA Details possible mechanisms of action on how rare cannabinoids can inter...

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held on March 9th are now available for online viewing. REGISTER NOW AT : ...

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum to be held March 9 th . Individual investors, institutional investors, advisors, and analysts ...

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the Company's executive t...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company clos...

InMed Pharmaceuticals press release ( NASDAQ: INM ): Q2 GAAP EPS of -$0.91. Revenue of $0.47M (+74.1% Y/Y). Approaches completion of enrollment for Ph 2 clinical trial in EB Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such ...

Closed calendar year 2022 with strong cash position of $11.5 million Approaches completion of enrollment for Ph 2 clinical trial in EB Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and ...